Doug Drysdale, CEO, Cybin
Cybin’s CEO, Doug Drysdale, shares update on sublingual psilocybin treatment for depression, and more.
Psychedelic Spotlight Podcast · Global Trac Solutions Inc., Doug Drysdale, Cybin, Psychedelic Spotlight, David Flores
Audio is streamed directly from the publisher (cdn.simplecast.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In today’s episode of the Psychedelic Spotlight podcast, we sit down with Doug Drysdale, CEO of Cybin, a biotechnology company focused on creating new, effective, and accessible psychedelic-based therapies.
In our conversation, Doug talks about the company’s mission to revolutionize mental healthcare, how Cybin is delivering powerful and effective therapies, and why being the first psychedelic-based company to list on the New York Stock Exchange was a natural fit. Cybin can be found on the NYSE under the ticker symbol $CYBN.
*To learn more about Cybin and the work they’re doing, visit their website: Cybin.com
*Subscribe to our newsletter to get the latest industry news: PsychedelicSpotlight.com
Instagram: @PsycSpotlight
Twitter: @PsycSpotlight
Facebook: PsychedelicSpotlight
YouTube: PsychedelicSpotlight
LinkedIn: Psychedelic-Spotlight
*This interview was recorded on September 2, 2021.